🏛️ Verified NIH Record • Updated 2026-08-05
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) (NCT07151391)
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Utah
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
Who can join: Review the eligibility criteria below.
Location: Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (801) 585-3453
Email: susan.sharry@hci.utah.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroendocrine Tumors
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients — Denver, Colorado
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors — Hamilton, Ontario
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors — Iowa City, Iowa
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Gilbert, Arizona
- Post-Authorization Long-Term Safety Study of LUTATHERA — Phoenix, Arizona
- Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors — Edmonton, Alberta
Explore by condition: All Neuroendocrine Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.